New Biocompatible Haemodiafiltration Membrane to Enable Maximum Substitution for Sensitive Patients

This symposium took place on 5th June 2017, as part of the 54th European Renal Association – European Dialysis and Transplant Association (ERA–EDTA) Congress in Madrid, Spain

Chairperson: Rafael Selgas1
Speakers: Francisco Maduell,2 Tadashi Tomo3

1. Nephrology Department, Hospital General Universitario La Paz, Madrid, Spain
2. Nephrology Department, Hospital ClÍnic, Barcelona, Spain
3. Clinical Engineering Research Center, Faculty of Medicine, Oita University, Oita, Japan

Disclosure: Prof Dr Rafael Selgas has declared no conflicts of interest. Dr Francisco Maduell received travel refunds and congress registration fees from Amgen, Baxter, Fresenius, Medtronic, and Nipro. Dr Tadashi Tomo received travel refunds from Nipro.
Acknowledgements: Writing assistance was provided by Jane Tricker, ApotheCom, London, UK.
Support: The publication of this article was funded by Nipro Medical Europe. The views and opinions expressed are those of the authors and not necessarily of Nipro Medical Europe.
Citation: EMJ Nephrol. 2017;5[1]:43-50.

Meeting Summary

In many European countries, high-volume online haemodiafiltration (OL-HDF) is becoming the method of choice for treating patients with chronic kidney disease. The high convective (Qs >20 L/session) and diffusive properties of this treatment have been shown to be beneficial for patient survival. For optimum outcomes, the dialyser membrane must be able to cope with high transmembrane pressures. For this reason, the most widely-used membranes for this technique are synthetic and asymmetric in structure, making it easier for the membrane to divert the pressure away from its surface. However, patients allergic or sensitive to synthetic molecules, cannot access these high convective volumes (CV) reached in high-volume HDF, because alternative semi-natural membranes for allergic patients, such as cellulose acetate-based membranes, do not have adequate pressure-handling properties for high-volume HDF.

At this symposium, a new type of cellulose triacetate (CTA)-based membrane that is biocompatible, able to perform high-volume OL-HDF, and suitable for sensitive patients was introduced.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Download (PDF, 425KB)

Comments are closed.